4.8 Article

Zinc-Organometallic Framework Vaccine Controlled-Release Zn2+ Regulates Tumor Extracellular Matrix Degradation Potentiate Efficacy of Immunotherapy

Journal

ADVANCED SCIENCE
Volume -, Issue -, Pages -

Publisher

WILEY
DOI: 10.1002/advs.202302967

Keywords

immunotherapy; tumor extracellular matrix; vaccine; zinc-organometallic framework; Zn2+

Ask authors/readers for more resources

This article reports a zinc-organometallic framework vaccine (ZPM@OVA-CpG) prepared by self-assembly, which achieves site-directed release of zinc ions in dendritic cell (DC) lysosomes and tumor microenvironment under acidic conditions, significantly enhancing the cGAS-STING signal and promoting the activation of CD8(+) T cells. Moreover, the vaccine reaches the tumor site, releases zinc ions, and degrades collagen components of tumor ECM, effectively alleviating immune suppression and enhancing the infiltration and killing of CD8(+) T cells.
Tumor extracellular matrix (ECM) not only forms a physical barrier for T cells infiltration, but also regulates multiple immunosuppressive pathways, which is an important reason for immunotherapy failure. The cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway plays a key role in activating CD8(+) T cells, maintaining CD8(+) T cells stemness and enhancing the antitumor effect. Herein, a zinc-organometallic framework vaccine (ZPM@OVA-CpG) prepared by self-assembly, which achieves site-directed release of Zn2+ in dendritic cell (DC) lysosomes and tumor microenvironment under acidic conditions, is reported. The vaccine actively targets DC, significantly enhances cGAS-STING signal, promotes DC maturation and antigen cross-presentation, and induces strong activation of CD8(+) T cells. Meanwhile, the vaccine reaches the tumor site, releasing Zn2+, significantly up-regulates the activity of matrix metalloproteinase-2, degrades various collagen components of tumor ECM, effectively alleviates immune suppression, and significantly enhances the tumor infiltration and killing of CD8(+) T cells. ZPM@OVA-CpG vaccine not only solves the problem of low antigen delivery efficiency and weak CD8(+) T cells activation ability, but also achieves the degradation of tumor ECM via the vaccine for the first time, providing a promising therapeutic platform for the development of efficient novel tumor vaccines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available